Calithera Biosciences (NASDAQ:CALA) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report released on Saturday.

CALA has been the subject of several other research reports. ValuEngine lowered shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price target for the company in a report on Monday, November 6th. Finally, William Blair began coverage on shares of Calithera Biosciences in a report on Thursday, October 5th. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $15.17.

Calithera Biosciences (CALA) traded down $0.20 during trading hours on Friday, hitting $9.50. 427,823 shares of the stock traded hands, compared to its average volume of 990,383. Calithera Biosciences has a twelve month low of $3.00 and a twelve month high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. The business had revenue of $7.20 million during the quarter, compared to the consensus estimate of $6.02 million. sell-side analysts expect that Calithera Biosciences will post -0.77 earnings per share for the current year.

In related news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the business’s stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total transaction of $9,008,640.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 16.30% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in CALA. Vanguard Group Inc. grew its position in Calithera Biosciences by 99.8% during the 1st quarter. Vanguard Group Inc. now owns 925,015 shares of the biotechnology company’s stock worth $10,684,000 after purchasing an additional 462,137 shares during the last quarter. Geode Capital Management LLC grew its position in Calithera Biosciences by 61.6% during the 1st quarter. Geode Capital Management LLC now owns 107,169 shares of the biotechnology company’s stock worth $1,236,000 after purchasing an additional 40,841 shares during the last quarter. Morgan Stanley grew its position in Calithera Biosciences by 1,053.6% during the 1st quarter. Morgan Stanley now owns 98,161 shares of the biotechnology company’s stock worth $1,133,000 after purchasing an additional 89,652 shares during the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in Calithera Biosciences during the 1st quarter worth approximately $214,000. Finally, Schwab Charles Investment Management Inc. grew its position in Calithera Biosciences by 249.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 71,600 shares of the biotechnology company’s stock worth $1,064,000 after purchasing an additional 51,100 shares during the last quarter. 72.19% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Calithera Biosciences (CALA) Lowered to Strong Sell at BidaskClub” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/09/calithera-biosciences-cala-lowered-to-strong-sell-at-bidaskclub.html.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.